| Company Name: |
Dalian Meilun Biotech Co., Ltd.
|
| Tel: |
0411-62910999 13889544652 |
| Email: |
meilunui@163.com |
| Products Intro: |
Product Name:GSK-2879552.2HCl
CAS:1902123-72-1
Purity:>98%,BR Package:5MG
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Tel: |
400-1647117 13681763483 |
| Email: |
product02@bidepharm.com |
| Products Intro: |
Product Name:4-((4-((((1R,2S)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid dihydrochloride
CAS:1902123-72-1
Purity:98+% Package:25mg;50mg;100mg;250mg;1g Remarks:BD764845
|
| Company Name: |
Nanjing Tengyi Biotechnology Co., Ltd
|
| Tel: |
025-58851786 17714337195 |
| Email: |
sales@tybiochem.com |
| Products Intro: |
Product Name:GSK2879552 dihydrochloride
CAS:1902123-72-1
Purity:95+% Package:1g;5g
|
| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:GSK2879552 dihydrochloride
CAS:1902123-72-1
Purity:99% Package:10mg
|
|
| | GSK-2879552.2HCl Basic information |
| Product Name: | GSK-2879552.2HCl | | Synonyms: | Benzoic acid, 4-[[4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]-1-piperidinyl]methyl]-, hydrochloride (1:2);4-((4-((((1R,2S)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid dihydrochloride | | CAS: | 1902123-72-1 | | MF: | C23H29ClN2O2 | | MW: | 400.95 | | EINECS: | | | Product Categories: | | | Mol File: | 1902123-72-1.mol |  |
| | GSK-2879552.2HCl Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : 50 mg/mL (114.31 mM; Need ultrasonic) | | form | Solid | | color | White to off-white |
| | GSK-2879552.2HCl Usage And Synthesis |
| Biological Activity | GSK2879552 dihydrochloride an orally active, selective and irreversible inhibitor of lysine specific demethylase 1 (LSD1/KDM1A), with potential antineoplastic activity[1][2].
GSK2879552 inhibits KDM1A histone demethylase activity, inducing differentiation of sorafenib-resistant cells and attenuates stemness properties. GSK2879552 depresses the transcription of Wnt antagonists and downregulates β-catenin signaling activity in sorafenib-resistant cells[1].
GSK2879552 (1.5 mg/kg, p.o.) treatment exhibits tumor growth inhibition in SCLC xenograft bearing mice[2]. | | References | [1]. Huang M, et al. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. Cancer Lett. 2017 Apr 2;398:12-21. [2]. Mohammad HP, et al. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 2015 Jul 13;28(1):57-69. |
| | GSK-2879552.2HCl Preparation Products And Raw materials |
|